title: Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary.
abstract: OBJECTIVE
  Early stage primary carcinoma of the fallopian tube (PCFT) is an uncommon condition when strict criteria are applied. The aim of this study was to compare the outcome stage IA-IB PCFT to a matched group of ovarian cancer (OC).
  
  
  METHODS
  Between 1990 and 2008, 32 patients with stage IA-IB of PCFT were recorded in the database of three French Institutions. A control group of patients with OC was constituted.
  
  
  RESULTS
  Eleven eligible PCFT cases and 29 OC controls fulfilled the stringent inclusion criteria. Median follow-up was 70.2 months. Five-year overall survival was 83.3% (95% confidence interval [CI], 27.3 to 97.5) for PCFT and 88.0% (95% CI, 66.9 to 96.0) for OC (p=0.93). In the subgroup of patients with grade 2-3, the outcome was similar in PCFT compared to OC patients (p=0.75). Five-year relapse-free survival was respectively 62.5% (95% CI, 22.9 to 86.1) and 85.0% (95% CI, 64.6 to 94.2) in the PCFT and OC groups (p=0.07). In the subgroup of patients (grade 2-3), there was no difference between PCFT and OC (p=0.65).
  
  
  CONCLUSIONS
  The findings did not reveal any difference in prognosis between early stage of PCFT and OC when grade is taken into account. Management of PCFT should mirror that of ovarian carcinoma.
authors: Department of Surgery, Institut Claudius Regaud, Toulouse, France.
authors: Charlotte
authors: C
authors: Vaysse
authors: Cyril
authors: C
authors: Touboul
authors: Thomas
authors: T
authors: Filleron
authors: Eliane
authors: E
authors: Mery
authors: Eva
authors: E
authors: Jouve
authors: Pierre
authors: P
authors: Leguevaque
authors: Philippe
authors: P
authors: Morice
authors: Eric
authors: E
authors: Leblanc
authors: Denis
authors: D
authors: Querleu
references: Am J Surg Pathol. 2009 Mar;33(3):376-83
references: 19011565
references: Obstet Gynecol Surv. 1994 May;49(5):349-61
references: 8015756
references: Oncologist. 2006 Sep;11(8):902-12
references: 16951394
references: Cancer. 1989 Mar 1;63(5):836-8
references: 2914291
references: Clin Med Res. 2007 Mar;5(1):35-44
references: 17456833
references: J Clin Oncol. 2008 Sep 1;26(25):4160-5
references: 18757330
references: Gynecol Oncol. 1996 Aug;62(2):199-202
references: 8751549
references: Am J Obstet Gynecol. 1981 Sep 15;141(2):132-7
references: 7282787
references: J Gynecol Obstet Biol Reprod (Paris). 2005 Apr;34(2):154-61
references: 16108112
references: Gynecol Oncol. 2007 Dec;107(3):398-403
references: 17997146
references: Gynecol Oncol. 2009 Oct;115(1):97-101
references: 19615725
references: Obstet Gynecol. 1990 Dec;76(6):1020-4
references: 2234710
references: Gynecol Oncol. 1991 Mar;40(3):268-73
references: 2013452
references: Gynecol Oncol. 2004 Sep;94(3):624-9
references: 15350350
references: Cancer. 2000 Nov 15;89(10):2076-84
references: 11066048
references: Mod Pathol. 2009 Aug;22(8):985-8
references: 19407856
references: Obstet Gynecol. 1993 Nov;82(5):748-51
references: 8414320
references: Am J Surg Pathol. 2007 Feb;31(2):161-9
references: 17255760
references: Fertil Steril. 2007 Oct;88(4):906-10
references: 17920404
references: Gynecol Obstet Fertil. 2005 Jan-Feb;33(1-2):23-8
references: 15752662
references: Cancer. 2008 Dec 15;113(12):3298-306
references: 19006196
references: Gynecol Oncol. 1987 Mar;26(3):305-13
references: 3557196
references: Histopathology. 2008 Aug;53(2):127-38
references: 18298580